AJ-VACCINES
22.4.2020 08:10:11 CEST | Business Wire | Pressemeddelelse
På trods af en igangværende indsats for at udrydde polio, har der været en stigning af registrerede poliotilfælde fra 2018 til 2019. Fremadrettet vil AJ Vaccines ’ antigen reducerende teknologi give mulighed for at udvide udbuddet af poliovaccine, med potentiale for at levere op til 100 millioner doser i femårsperioden 2020-2024, hvilket vil dække den uopfyldte globale efterspørgsel på inaktiverede poliovacciner.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200421005974/da/
En milepælspræstation
Udviklingen af den første dosis reducerede enkelt-komponent inaktiverede poliovaccine er en milepæl for den betydelige investering og innovation, der er foretaget i den danske vaccineproduktion. ”WHO's prækvalifikation er en anerkendelse af vores fortsatte investeringer, som gør det muligt for AJ Vaccines at imødekomme den stigende efterspørgsel på effektive poliovacciner, og vi åbner hermed et nyt kapitel i virksomhedens fortsatte rejse mod at bistå den danske befolkning og et stigende antal mennesker globalt” , siger Mr. Abdulaziz Hamad Aljomaih, hovedinvestor i AJ Vaccines.
En hyldest til dedikerede medarbejdere
Opnåelsen af WHO-prækvalifikationen er en hyldest til medarbejderne for deres engagement og deres bidrag, som har involveret en omfattende gennemgang af produktionsprocesser og kvalitetskontrolprocedurer, uafhængig laboratorietestning, vurdering af filer samt en inspektion af produktionsfaciliteter, der er udført i fællesskab mellem WHO og Lægemiddelstyrelsen i 2019. ”Prækvalifikationen er en anerkendelse af vores engagerede medarbejderes kompetencer og ligger i forlængelse af vores virksomheds vision, der stræber efter en verden fri for alvorlige sygdomme på tværs af generationer” , siger dr. Tabassum Khan, formand for AJ Vaccines.
Betydelige investeringer
Picovax®-udviklingsprojektet er støttet af Bill & Melinda Gates Foundation. ”Siden vores overtagelse af AJ Vaccines i 2017 har vi investeret markant i den strategiske udvidelse af vores produktionsfaciliteter og rekrutteret 200 nye medarbejdere for at sikre AJ Vaccines’ position som en betydelig aktør på vaccinemarkedet, der bidrager til det vigtige strategiske globale mål om at udrydde polio” , siger Jesper Helmuth Larsen, administrerende direktør i AJ Vaccines.
Den nye vaccine vil spille en afgørende rolle for The Global Polio Eradication Initiative (GPEI)
Den nye inaktiverede poliovaccine (IPV) er indikeret til aktiv immunisering mod poliomyelitis ved primær vaccination hos spædbørn fra seks uger og til revaccination af spædbørn, børn og unge. En antigen reduceret IPV giver beskyttelse, der kan sammenlignes med den, der opnås ved andre inaktiverede poliovacciner, der i øjeblikket er tilgængelige. ”Den antigen reducerende teknologi sikrer en tiltrængt forøgelse i udbuddet og vil bidrage til at imødekomme det stigende behov for inaktiveret poliovacciner, der støtter The Global Polio Eradication Initiative” , afslutter Jérôme Cabannes, COO AJ Vaccines.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200421005974/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum